Keele, UK, 17th July 2006 – UK based Cobra Biomanufacturing Plc (AIM: CBF) and the Malvern, Pennsylvania based company Auxilium Pharmaceuticals, Inc., (Nasdaq: AUXL), today announces an important contract to produce further cGMP batches and three BLA (Biologics Licence Application) batches of AA4500. This work will complete by calendar year end 2006 and, during this period, Cobra Biomanufacturing and Auxilium Pharmaceuticals will be discussing the terms of a non-exclusive long-term manufacturing agreement for the commercial supply requirements of AA4500. 

David Thatcher, Chief Executive of Cobra Biomanufacturing, commented:

“This contract represents an important step in Cobra’s evolution from a supplier of early stage clinical trials materials into a supplier of commercial quantities of licensed products. Cobra’s current contracted forward order book is now £8.6m of which £5.4m is deliverable in the current financial year.” 

-Ends- 

For further information:

Cobra Biomanufacturing Plc       

Tel: 44 (0) 1782 714 181

David Thatcher, Chief Executive              

Northbank Communications

Tel: 44 (0) 1260 296 5000

Marc Egelhofer             

Buchanan Communications

Tel: 44 (0) 207 466 5000

Tim Anderson/Mark Court/Rebecca Dietrich       

Notes to Editors: 

About Cobra Biomanufacturing Plc:

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra was the first company to develop GMP (Good Manufacturing Practice) standard DNA manufacture in Europe, with specific expertise in DNA medicines. A range of unique, patented technologies, underpins this revenue generating business.

Cobra floated on the AIM market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. www.cobrabio.com  

About Auxilium Pharmaceuticals:

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focus on developing and marketing products for urology, sexual health and other indications within specialty markets.  Auxilium markets Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 130-person sales and marketing team.  Auxilium has five projects in clinical development.  Auxilium believes that AA4500, an injectable enzyme, has completed Phase II of development for the treatment of Dupuytren’s Disease and is in Phase II of development for the treatment of Peyronie’s Disease and Frozen Shoulder Syndrome (Adhesive Capsulitis).  Auxilium’s testosterone replacement transmucosal film product candidate for the treatment of hypogonadism (AA2600) is in Phase III of development.  Auxilium’s transmucosal film product candidate for the treatment of overactive bladder (AA4010) is in Phase I of development.  Auxilium has two pain products using its transmucosal film delivery system in pre-clinical development.  Auxilium has rights to six additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system, options to all indications using AA4500 for non-topical formulations, and other products for urology and sexual health.  For additional information, visit www.auxilium.com.